Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

AstraZeneca plc (ADR) (AZN), Sanofi SA (ADR) (SNY): Don’t Ignore These European Healthcare Stocks

Healthcare stocks have rallied over the past couple years, and for good reason. Not only is the global economy gaining traction, but the demographic trends, particularly in the United States, are extremely favorable. It’s a cliché by now, but it’s still true, that America is an aging society. The Baby Boomer generation is rapidly approaching retirement, and in turn will require a great deal of healthcare services.

As a result, when many investors view healthcare stocks, they tend to focus on the U.S. pharmaceutical giants. While those companies are certainly worthy of investment consideration, there happen to be foreign companies with significant exposure to the U.S. economy that are equally worthy of your investment dollars.

AstraZeneca plc (ADR) (NYSE:AZN)

Profits from across the pond

You may not know these international pharmaceutical giants, but they have the same characteristics that make their American counterparts so attractive: namely, steady fundamentals and hefty dividend yields.

In some cases, these healthcare giants may actually provide more in terms of yield than their U.S. peers. For example, AstraZeneca plc (ADR) (NYSE:AZN) carries one of the biggest yields among the publicly-traded big pharma stocks.

Based in the United Kingdom, AstraZeneca plc (ADR) (NYSE:AZN) might not sound familiar to many investors, but many of its key products probably ring a bell. Among the company’s better known drugs are Crestor, Nexium, and Atacand.

As previously mentioned, perhaps the best feature of owning AstraZeneca plc (ADR) (NYSE:AZN) is its massive dividend. The company pays a semi-annual dividend, which yields close to 6% annualized.

Furthermore, AstraZeneca plc (ADR) (NYSE:AZN) isn’t expensively valued. Whereas many U.S. pharmaceutical giants trade close to 20 times trailing earnings, AstraZeneca plc (ADR) (NYSE:AZN) changes hands for a much more attractive 10 times trailing EPS.

Other international candidates for your watch list are Novartis AG (ADR) and Sanofi SA (ADR) (NYSE:SNY). Both of these companies are giants, with the market values and dividends to prove it.

Novartis AG (ADR) is based in Switzerland and has a long history, founded all the way back in 1895. The company holds a $173 billion market capitalization.

Novartis AG (ADR) reported mixed full-year 2012 results. Sales were flat on a constant currency basis, but core earnings per share dropped 3% versus the prior year. However, Novartis AG (ADR) was pleased with its performance amid the challenging 2012 economy and provided investors with the 16th consecutive annual dividend increase. The company’s current payout yields 3.5% at recent prices.

Like Novartis, France-based Sanofi SA (ADR) (NYSE:SNY) performed admirably last year, which proved difficult due to the struggling European economy, in addition to patent expiration. Total sales grew half of one percent, even though the company lost more than 1.3 billion euros due to generic competition.

Going forward, management expects the company’s difficulties to continue this year. Sanofi SA (ADR) (NYSE:SNY) projects 2013 earnings per share to be flat to down 5% for the full year, due primarily to residual impacts from the company’s loss of Plavix and Avapro exclusivity in the United States.

That being said, the company’s troubles certainly aren’t being reflected in the stock price. Sanofi SA (ADR) (NYSE:SNY) has skyrocketed 43% over the past 52 weeks and currently sits near all-time highs, and that doesn’t even include the hefty 3.3% dividend.

The Foolish bottom line

For investors looking for international competitors of the familiar healthcare giants in the United States, these companies are a good place to start. These stocks offer reasonable valuations and huge dividend yields that are greater than the broader market as well as most industry peers.

It’s worth noting that these companies are based in Europe, and as a result, have significant exposure to the shaky European economy. That being said, these multi-nationals performed admirably in a tough 2012 environment, indicative of their strong product pipelines and global reach.

At the same time, investors are being paid handsomely to wait for the global economy to return to more solid footing. Should the European economy in particular finally show some strength, these companies may be set up very well going forward. As a result, income investors will want to keep these names on your watch list going forward.

The article Don’t Ignore These European Healthcare Stocks originally appeared on Fool.com and is written by Robert Ciura.

Robert Ciura has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Robert is a member of The Motley Fool Blog Network — entries represent the personal opinion of the blogger and are not formally edited.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.